In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that ...

The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory systemic light chain amyloidosis, according to phase 1/phase 2 trial results ...

AstraZeneca announces CARES phase III clinical programme fails to meet primary endpoint in overall light chain amyloidosis population: Cambridge, UK Monday, June 1, 2026, 12:00 Hr ...

Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No ...

Based on these results, Prothena has made the decision to discontinue the development of birtamimab. Topline results were announced from a phase 3 trial evaluating birtamimab in patients with amyloid ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a ...

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or ...